Skip to main content
. Author manuscript; available in PMC: 2016 Jun 20.
Published in final edited form as: Eur J Immunol. 2015 Feb 26;45(5):1313–1325. doi: 10.1002/eji.201445319

Figure 1. Repeated CpG treatment impairs B-cell lymphopoiesis.

Figure 1

(A– F) C57BL6 mice were treated with PBS or CpG five times over ten days. (A) Bone marrow cell numbers from both tibias and femurs were determined by cell counting with trypan blue. Each dot represents an individual mouse, bars show mean +/− SEM. (B) DCs (CD11c+ NK1.1−, GR-1−), Macrophages (GR-1+ CD11blo), Granulocytes (GR-1+ CD11bhi) and B cells (CD19+) were discriminated by flow cytometry and numbers were calculated using total bone marrow cellularity as determined in (A). Bars show mean +SEM C) CLPs (Lineage−, cKitint, Sca-1low/high, IL-7Rα+, Flt3+) discriminated on expression of Ly-6D, Pro (B220int, Aa4.1+, CD19+, IgM−, CD43+), Pre (B220int, Aa4.1+, CD19+, IgM−, CD43−), and Immature B-cell (B220int, Aa4.1+, CD19+, IgM+) numbers from treated mice. D) Total splenic B cell (CD19+) population numbers. E) Total thymocyte numbers. F) Thymocyte subsets DN1 (CD4−, CD8−, cKit+, CD25−), DN2 (CD4−, CD8−, cKit+, CD25+), DN3 (CD4−, CD8−, cKit−, CD25+), DN4 (CD4−, CD8−, cKit−, CD25−), DN (CD4−, CD8−), DP (CD4+, CD8+), CD4 (CD4+, CD8−), CD8 (CD4−, CD8+). (A–F) Data are representative of 5 independent experiments with 4–5 mice per group. * = p<0.05, ** = p<0.005 by unpaired t-test. Error bars represent SEM.